Updated:
Immunome
Immunome was founded in 2015 and is headquartered in Bothell, Washington. The company went public via a reverse merger with a cash-rich shell in 2020.
Immunome
Immunome was founded in 2015 and is headquartered in Bothell, Washington. The company went public via a reverse merger with a cash-rich shell in 2020. Its research platform uses human memory B cells from patients who respond well to immunotherapies to discover novel antibody-drug conjugates and immunotherapeutic targets. The firm is focused on oncology, with its lead program targeting specific solid tumors. Immunome operates as a clinical-stage biotechnology company rather than a traditional asset manager or family office. Its strategy centers on developing first-in-class cancer therapies. Following the merger with Morphimmune in 2023, the company gained a pipeline of next-generation antibody-drug conjugate candidates. In 2024 Clay Siegall, the former CEO of Seagen who architected its $43 billion sale to Pfizer, was appointed Chairman and CEO. He immediately led a push to refocus the pipeline and allocate capital toward advancing lead candidates into mid-late stage trials, with confirmed programs aimed in part at ovarian and other solid tumors. The company reported approximately $270 million in cash at the end of the first quarter of 2024, providing a clear runway to fund operations into 2026. The headquarters remain in Bothell, Washington with additional operations in Philadelphia, Pennsylvania from the Morphimmune legacy. The firm has no disclosed external fundraising vehicles or philanthropic arms, operating as a single public entity utilizing its balance sheet to advance internal programs. Immunome's structural distinction lies in its post-reverse-merger rebirth under a CEO with a demonstrable record of building and selling a major oncology platform. This is not a steady-state biotech but a deliberate recapitalization vehicle with a named operator brought in to run a focused, cash-backed execution play on a specific therapeutic modality.
General information
Firm type
Asset Manager
Year founded
2015
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Bothell
Corporate office
Bothell, WA, United States
Principals
Clay B. Siegall
Chairman and CEO
Sector focus
Frequently asked questions
Who runs Immunome and what is their track record?
Clay B. Siegall became Chairman and CEO in March 2024. He previously co-founded Seagen and built it into a leading oncology company, culminating in its $43 billion acquisition by Pfizer in 2023. His appointment signals a strategic pivot to aggressively advance the pipeline with a leadership team that has executed major biotech exits.
How does Immunome's discovery platform work?
Immunome uses patient-derived memory B cells from individuals who show exceptional responses to immunotherapy. By isolating these cells and identifying their target antigens, the firm aims to discover novel oncology targets and develop first-in-class antibody-based therapies, including antibody-drug conjugates.
What is Immunome's current financial position?
As of the first quarter of 2024, Immunome reported having roughly $270 million in cash. Management has stated this provides a runway into 2026, sufficient to fund its clinical programs through key data readouts without needing to raise additional capital immediately.
Is Immunome a family office or an operating biotech company?
Immunome is a publicly traded clinical-stage biopharmaceutical company. It is not a family office. It conducts internal drug discovery and development, and its capital comes from public markets rather than managing a private family's wealth.
What is Immunome's lead drug candidate?
The firm's pipeline is focused on antibody-drug conjugates targeting solid tumors. Specific programs have been disclosed targeting ovarian cancer and other malignancies. The pipeline was reshaped following the 2023 merger with Morphimmune which brought in additional preclinical and clinical ADC assets.
How did Immunome become a public company?
Immunome went public through a reverse merger in 2020. More recently, in 2023, it merged with Morphimmune, which not only added a new pipeline of antibody-drug conjugate programs but also brought a substantial cash position to the combined entity, effectively recapitalizing the company.
Does Immunome make external venture investments or co-investments?
No. Immunome operates as a therapeutics company developing its own internal pipeline. There is no evidence of a venture capital arm or a mandate to co-invest alongside other institutional investors or family offices.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: